New stroke drug LT3001 passes first safety check in healthy volunteers

NCT ID NCT04809818

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tested the safety of LT3001, a potential clot-busting drug for acute ischemic stroke, in 65 healthy adults. Participants received multiple doses of LT3001 alone or with common stroke medications like aspirin and clopidogrel. The goal was to check for side effects and how the drug interacts with other treatments, not to measure effectiveness against stroke.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LT3001 injection

What this could lead to

If successful, this could pave the way for a new stroke treatment that dissolves clots and may be safer when used with other medications.

What could go wrong

This is an early Phase 1 study in healthy volunteers, not stroke patients. It only tests safety and drug interactions, not whether LT3001 actually treats strokes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Lumosa Phase 1 Unit

    Cypress, California, 90630, United States